Search: 2017 AP Meeting Faculty
Results 1 - 6 of 6

Stephen Griffiths

Publications Lead, Asia-Pacific, Medical Affairs

Type of Company:
Professional Degrees: BA/BS, PhD

Bio: Stephen Griffiths is currently Publications Lead for Asia-Pacific at GSK Vaccines, based in Singapore. He has almost 10 years of industry experience, first in R&D for pharma (GSK) and biotech (Arrow Therapeutics; later acquired by AstraZeneca) then as Principal Medical Writer and Scientific Advisor for the medical communications company Nucleus Global. During his medical communications career to date he has worked on various medical and commercial projects across all stages of the product lifecycle for several top pharma companies. He holds a PhD from University College London and the Royal Free Hospital in the field of virology and immunology, with research experience at Cincinnati Children's Hospital in the US and National University Hospital in Singapore.

Mieko Hamana

Associated Director, Medical Affairs
Astellas Pharma Inc.

Type of Company:
Professional Degrees: CMPP, *Other
Other Degrees*: postgraduate
CMPP Certified: 3/2015

Bio: Mieko is a Certified Medical Publication Professional and has the extensive experience required for a pharmaceutical company to successfully pursue publication activities. Deep knowledge of publication ethics and good practices, as well strategic planning and implementation capabilities, are required. Mieko has had a broad-ranging career, developed by working in medical affairs, marketing, development, HEOR, product and portfolio assessment, and resource planning associated with product development. In addition, her 10-year experience as a global lead to manage one of her company's leading urology products served to enhance her strength in managing diverse requirements. In moving to medical affairs, Mieko has been actively engaged in publication policy/SOP setting, auditing, and educational activities. She has been an invited speaker at various meetings organized by entities in domestic and overseas including ISMPP.

Brian Hepburn

Envision Pharma Group

Bio: Brian Hepburn is the founder and CEO of the Envision Pharma Group, a full service, technology-enabled agency that supports Medical Affairs through scientific communication services and purpose-built technology solutions. During his 16-years at the helm, the Medical Affairs landscape has undergone extensive changes. Patient centricity, pricing pressures, increased transparency, and industry guidelines (eg, GPP3) have influenced the environment in which Envision operates, including the Asia Pacific region. As Envision has grown, Brian and his team have strived to stay ahead of this changing environment, assisting clients to produce effective, ethical, and compliant medical communications, and ultimately, to facilitate the transition of innovative treatments into the clinic. To assist Envisions clients in this endeavour, Brian has driven the evolution of Envision, adding services such as Medical Strategy and HEOR/Market Access consultancy, in addition to a range of purpose-built software solutions beyond Datavision. Given the increasing importance of the Asia Pacific region in the global drive for healthcare innovation, Brian prioritised expansion of Envision's Tokyo and Sydney offices, leveraging the local expertise of Envision's CMPP-qualified staff who have been living and working in the Asia Pacific region for almost 20 years.

Noriaki Hosoya

Medical Publications Manager, Medical Capabilities
Bristol-Myers Squibb K.K.

Type of Company:
Professional Degrees: PhD

Bio: Noriaki Hosoya has worked as publication lead at Bristol-Myers Squibb K.K., Tokyo, Japan, since April 2015. In this role, he covered publications in the therapeutic areas of hematology, immuno-oncology and immunology in his first year, and currently covers publications in the therapeutic areas of hematology, hepatitis C virus and cardiovascular disease as publication lead. Noriaki received a doctor degree from the University of Tokyo in 2005. He previously worked as a basic researcher of HIV immunology and virology at the Brigham and Women's Hospital, Boston MA, USA, from 2005-2008 and the Institute of Medical Science, the University of Tokyo, from 2009-2015.

Chris Hourigan

Janssen Japan KK

Bio: Chris Hourigan is President, Janssen Japan and a member of the Janssen Asia Pacific Leadership Team. Before moving into his current role in Japan, Chris was the Managing Director for Janssen Australia & New Zealand (ANZ), where he developed strong business leaders among his team and also played a key role in supporting the local industry as a member of the Medicines Australia Board. Chris also initiated the development of a Johnson & Johnson signature program for disadvantaged indigenous populations in collaboration with the local J&J Board. Before leading Janssen ANZ, Chris was the Managing Director of Janssen Vietnam, where he focused on building a long-term strategy to drive transformational growth for the pharmaceutical business in this high growth AP market. Before this role, Chris was Country Manager for Janssen New Zealand and a board member of the industry association, Medicines New Zealand, and the Janssen Australia New Zealand Leadership Team. During 2008 and 2009, he was the Global Marketing Leader for Psychiatry based in the USA, where he led the development of the antipsychotic long-acting franchise, including Risperdal Consta and Invega Sustenna. Chris joined Johnson and Johnson through Janssen Australia in 2005, as the Marketing Manager for the General Medicine franchise. In 2006, he was appointed Associate Business Unit Director for CNS and also had Asia Pacific regional marketing responsibility for Concerta. In the 13 years before joining J&J, he worked for other pharmaceutical companies. Chris holds a Masters of Business Administration and a Bachelor of Applied Science.

Nobuhiko Ishizuka

Senior Leader, Medical Affair
Chugai Pharmaceutical Co. Ltd.

Type of Company:
Professional Degrees: PhD

Bio: After graduating from the veterinary pharmacology department at Gifu University, Ishizuka joined Chugai Pharmaceutical as a cardiovascular researcher. His PhD research was involving pharmacology of Na/K ATPase isozyme working in the pediatric pharmacology lab at National Children's Medical Research Center of Japan and in the physiology lab at Bockus Research Institute in University of Pennsylvania. Then, he spent 2 weeks at KRICT in Korea as a UNDP consultant to share the laboratory standards for pharmaceutical development. During last decade, he gained peer-review experience requested from the several basic scientific journals, and have become an editorial board member. His current role in medical affairs division includes aligning processes with the global publication standard, medical writing, and publication management of antibody biologics against autoimmune diseases in rheumatology, dermatology, and neurology.